Biodesix, Inc. (NASDAQ: BDSX) Stock Competitors & Peer Comparison
See BDSX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BDSX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BDSX | $28.17 | +2.80% | 225.5M | -8.74 | -$3.17 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.69% |
| TMO | $647.89 | +5.67% | 238.4B | 27.70 | $23.16 | +0.29% |
| DHR | $209.36 | +3.01% | 147.1B | 26.23 | $7.98 | +0.69% |
| NTRA | $349.44 | +2.24% | 50.2B | -265.74 | -$1.32 | N/A |
| IQV | $270.94 | +1.98% | 44.4B | 22.22 | $12.13 | N/A |
| A | $153.58 | +4.62% | 42.4B | 25.85 | $5.81 | +0.67% |
| IDXX | $519.83 | +2.02% | 40.3B | 35.92 | $14.22 | N/A |
| ILMN | $228.00 | +9.51% | 33.6B | 44.19 | $5.03 | N/A |
| WAT | $420.59 | +2.58% | 31.2B | 30.49 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
BDSX vs DHR-PB Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, BDSX's ROE is -7.88%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, BDSX is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
BDSX vs TMO Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, TMO has a market cap of 238.4B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while TMO trades at $647.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas TMO's P/E ratio is 27.70. In terms of profitability, BDSX's ROE is -7.88%, compared to TMO's ROE of +0.13%. Regarding short-term risk, BDSX is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
BDSX vs DHR Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, DHR has a market cap of 147.1B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while DHR trades at $209.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas DHR's P/E ratio is 26.23. In terms of profitability, BDSX's ROE is -7.88%, compared to DHR's ROE of +0.08%. Regarding short-term risk, BDSX is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
BDSX vs NTRA Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, NTRA has a market cap of 50.2B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while NTRA trades at $349.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas NTRA's P/E ratio is -265.74. In terms of profitability, BDSX's ROE is -7.88%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, BDSX is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
BDSX vs IQV Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, IQV has a market cap of 44.4B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while IQV trades at $270.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas IQV's P/E ratio is 22.22. In terms of profitability, BDSX's ROE is -7.88%, compared to IQV's ROE of +0.22%. Regarding short-term risk, BDSX is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
BDSX vs A Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, A has a market cap of 42.4B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while A trades at $153.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas A's P/E ratio is 25.85. In terms of profitability, BDSX's ROE is -7.88%, compared to A's ROE of +0.20%. Regarding short-term risk, BDSX is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
BDSX vs IDXX Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, IDXX has a market cap of 40.3B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while IDXX trades at $519.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas IDXX's P/E ratio is 35.92. In terms of profitability, BDSX's ROE is -7.88%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, BDSX is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
BDSX vs ILMN Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ILMN has a market cap of 33.6B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ILMN trades at $228.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ILMN's P/E ratio is 44.19. In terms of profitability, BDSX's ROE is -7.88%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, BDSX is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
BDSX vs WAT Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, WAT has a market cap of 31.2B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while WAT trades at $420.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas WAT's P/E ratio is 30.49. In terms of profitability, BDSX's ROE is -7.88%, compared to WAT's ROE of +0.02%. Regarding short-term risk, BDSX is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
BDSX vs DGX Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, DGX has a market cap of 27.3B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while DGX trades at $246.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas DGX's P/E ratio is 24.39. In terms of profitability, BDSX's ROE is -7.88%, compared to DGX's ROE of +0.14%. Regarding short-term risk, BDSX is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
BDSX vs MTD Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, MTD has a market cap of 26.9B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while MTD trades at $1,376.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas MTD's P/E ratio is 30.58. In terms of profitability, BDSX's ROE is -7.88%, compared to MTD's ROE of -12.00%. Regarding short-term risk, BDSX is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
BDSX vs LH Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while LH trades at $324.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas LH's P/E ratio is 18.72. In terms of profitability, BDSX's ROE is -7.88%, compared to LH's ROE of +0.12%. Regarding short-term risk, BDSX is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
BDSX vs GH Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, GH has a market cap of 23.6B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while GH trades at $176.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas GH's P/E ratio is -50.33. In terms of profitability, BDSX's ROE is -7.88%, compared to GH's ROE of +2.11%. Regarding short-term risk, BDSX is more volatile compared to GH. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
BDSX vs EXAS Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas EXAS's P/E ratio is -95.37. In terms of profitability, BDSX's ROE is -7.88%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, BDSX is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
BDSX vs MEDP Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, MEDP has a market cap of 17.3B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while MEDP trades at $618.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas MEDP's P/E ratio is 36.37. In terms of profitability, BDSX's ROE is -7.88%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, BDSX is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
BDSX vs ILMNV Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ILMNV's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to ILMNV's ROE of N/A. Regarding short-term risk, BDSX is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
BDSX vs RVTY Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, RVTY has a market cap of 15.6B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while RVTY trades at $145.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas RVTY's P/E ratio is 26.19. In terms of profitability, BDSX's ROE is -7.88%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, BDSX is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
BDSX vs PKI Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas PKI's P/E ratio is 41.45. In terms of profitability, BDSX's ROE is -7.88%, compared to PKI's ROE of +0.03%. Regarding short-term risk, BDSX is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check PKI's competition here
ICON Public Limited Company (NASDAQ: ICLR)
BDSX vs ICLR Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ICLR has a market cap of 13.2B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ICLR trades at $174.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ICLR's P/E ratio is 14.07. In terms of profitability, BDSX's ROE is -7.88%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, BDSX is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check ICLR's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
BDSX vs CRL Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CRL trades at $279.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CRL's P/E ratio is 27.53. In terms of profitability, BDSX's ROE is -7.88%, compared to CRL's ROE of -0.08%. Regarding short-term risk, BDSX is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check CRL's competition here
Qiagen N.V. (NYSE: QGEN)
BDSX vs QGEN Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, QGEN has a market cap of 8.8B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while QGEN trades at $43.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas QGEN's P/E ratio is 17.55. In terms of profitability, BDSX's ROE is -7.88%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, BDSX is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
BDSX vs RDNT Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, RDNT has a market cap of 6.1B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while RDNT trades at $77.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas RDNT's P/E ratio is 167.65. In terms of profitability, BDSX's ROE is -7.88%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, BDSX is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
BDSX vs SHC Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, SHC has a market cap of 5.4B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while SHC trades at $19.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas SHC's P/E ratio is 19.77. In terms of profitability, BDSX's ROE is -7.88%, compared to SHC's ROE of +0.27%. Regarding short-term risk, BDSX is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
BDSX vs BLLN Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, BLLN has a market cap of 4.8B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while BLLN trades at $105.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas BLLN's P/E ratio is 148.96. In terms of profitability, BDSX's ROE is -7.88%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, BDSX is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
BDSX vs SYNH Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas SYNH's P/E ratio is 61.40. In terms of profitability, BDSX's ROE is -7.88%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, BDSX is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check SYNH's competition here
GRAIL Inc. (NASDAQ: GRAL)
BDSX vs GRAL Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, GRAL has a market cap of 3.3B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while GRAL trades at $76.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas GRAL's P/E ratio is -7.78. In terms of profitability, BDSX's ROE is -7.88%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, BDSX is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check GRAL's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
BDSX vs OLK Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas OLK's P/E ratio is -96.59. In terms of profitability, BDSX's ROE is -7.88%, compared to OLK's ROE of -0.07%. Regarding short-term risk, BDSX is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check OLK's competition here
Veracyte, Inc. (NASDAQ: VCYT)
BDSX vs VCYT Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, VCYT has a market cap of 3.2B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while VCYT trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas VCYT's P/E ratio is 20.07. In terms of profitability, BDSX's ROE is -7.88%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, BDSX is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
BDSX vs WGS Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, WGS has a market cap of 2.8B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while WGS trades at $98.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas WGS's P/E ratio is 262.89. In terms of profitability, BDSX's ROE is -7.88%, compared to WGS's ROE of -0.39%. Regarding short-term risk, BDSX is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check WGS's competition here
CareDx, Inc (NASDAQ: CDNA)
BDSX vs CDNA Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CDNA trades at $54.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CDNA's P/E ratio is 62.67. In terms of profitability, BDSX's ROE is -7.88%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, BDSX is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check CDNA's competition here
Personalis, Inc. (NASDAQ: PSNL)
BDSX vs PSNL Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while PSNL trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas PSNL's P/E ratio is -14.77. In terms of profitability, BDSX's ROE is -7.88%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, BDSX is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
BDSX vs OPK Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while OPK trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas OPK's P/E ratio is -5.81. In terms of profitability, BDSX's ROE is -7.88%, compared to OPK's ROE of -0.06%. Regarding short-term risk, BDSX is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
BDSX vs CSTL Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CSTL trades at $35.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CSTL's P/E ratio is -53.79. In terms of profitability, BDSX's ROE is -7.88%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, BDSX is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
BDSX vs FLGT Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, FLGT has a market cap of 604.4M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while FLGT trades at $21.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas FLGT's P/E ratio is 2128.00. In terms of profitability, BDSX's ROE is -7.88%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, BDSX is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
BDSX vs GRALV Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas GRALV's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to GRALV's ROE of N/A. Regarding short-term risk, BDSX is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
BDSX vs NEO Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, NEO has a market cap of 485.4M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while NEO trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas NEO's P/E ratio is 145.31. In terms of profitability, BDSX's ROE is -7.88%, compared to NEO's ROE of -0.06%. Regarding short-term risk, BDSX is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
BDSX vs CO Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CO's P/E ratio is 5.06. In terms of profitability, BDSX's ROE is -7.88%, compared to CO's ROE of +0.11%. Regarding short-term risk, BDSX is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
BDSX vs MYGN Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, MYGN has a market cap of 366.5M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while MYGN trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas MYGN's P/E ratio is -29.85. In terms of profitability, BDSX's ROE is -7.88%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, BDSX is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check MYGN's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
BDSX vs FLDM Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas FLDM's P/E ratio is -4.74. In terms of profitability, BDSX's ROE is -7.88%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, BDSX is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check FLDM's competition here
Prenetics Global Limited (NASDAQ: PRENW)
BDSX vs PRENW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, PRENW has a market cap of 277.8M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas PRENW's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, BDSX is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check PRENW's competition here
Exagen Inc. (NASDAQ: XGN)
BDSX vs XGN Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, XGN has a market cap of 181M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while XGN trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas XGN's P/E ratio is -9.25. In terms of profitability, BDSX's ROE is -7.88%, compared to XGN's ROE of -1.22%. Regarding short-term risk, BDSX is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check XGN's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
BDSX vs IMDX Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, IMDX has a market cap of 129.8M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while IMDX trades at $3.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas IMDX's P/E ratio is -2.70. In terms of profitability, BDSX's ROE is -7.88%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, BDSX is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check IMDX's competition here
Genetron Holdings Limited (NASDAQ: GTH)
BDSX vs GTH Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas GTH's P/E ratio is -1.11. In terms of profitability, BDSX's ROE is -7.88%, compared to GTH's ROE of -1.01%. Regarding short-term risk, BDSX is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
BDSX vs GENE Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas GENE's P/E ratio is -38.25. In terms of profitability, BDSX's ROE is -7.88%, compared to GENE's ROE of -1.85%. Regarding short-term risk, BDSX is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
BDSX vs SERA Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, SERA has a market cap of 76M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas SERA's P/E ratio is -3.06. In terms of profitability, BDSX's ROE is -7.88%, compared to SERA's ROE of -0.47%. Regarding short-term risk, BDSX is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
BDSX vs PRPO Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while PRPO trades at $25.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas PRPO's P/E ratio is -104.77. In terms of profitability, BDSX's ROE is -7.88%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, BDSX is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
BDSX vs MDXH Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, MDXH has a market cap of 34.6M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while MDXH trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas MDXH's P/E ratio is -1.77. In terms of profitability, BDSX's ROE is -7.88%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, BDSX is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
BDSX vs QUCY Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, QUCY has a market cap of 30.5M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas QUCY's P/E ratio is -0.06. In terms of profitability, BDSX's ROE is -7.88%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, BDSX is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
BDSX vs AKU Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas AKU's P/E ratio is -0.13. In terms of profitability, BDSX's ROE is -7.88%, compared to AKU's ROE of -5.32%. Regarding short-term risk, BDSX is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
BDSX vs CEMI Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CEMI's P/E ratio is -0.63. In terms of profitability, BDSX's ROE is -7.88%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, BDSX is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
BDSX vs ENZ Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ENZ's P/E ratio is -2.24. In terms of profitability, BDSX's ROE is -7.88%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, BDSX is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
BDSX vs PMD Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas PMD's P/E ratio is -5.24. In terms of profitability, BDSX's ROE is -7.88%, compared to PMD's ROE of -0.32%. Regarding short-term risk, BDSX is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
BDSX vs ME Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ME's P/E ratio is -0.03. In terms of profitability, BDSX's ROE is -7.88%, compared to ME's ROE of -42.03%. Regarding short-term risk, BDSX is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
BDSX vs MYNZ Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, BDSX's ROE is -7.88%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, BDSX is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
BDSX vs BNR Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, BNR has a market cap of 12.2M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while BNR trades at $13.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas BNR's P/E ratio is -13.29. In terms of profitability, BDSX's ROE is -7.88%, compared to BNR's ROE of -0.13%. Regarding short-term risk, BDSX is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check BNR's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
BDSX vs ADVB Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ADVB has a market cap of 11.2M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ADVB trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ADVB's P/E ratio is -73.45. In terms of profitability, BDSX's ROE is -7.88%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, BDSX is more volatile compared to ADVB. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check ADVB's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
BDSX vs CHEK Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CHEK's P/E ratio is -0.43. In terms of profitability, BDSX's ROE is -7.88%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, BDSX is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
BDSX vs CNTG Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CNTG's P/E ratio is -0.23. In terms of profitability, BDSX's ROE is -7.88%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, BDSX is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
BDSX vs NDRA Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, NDRA has a market cap of 7.3M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while NDRA trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas NDRA's P/E ratio is -0.73. In terms of profitability, BDSX's ROE is -7.88%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, BDSX is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
BDSX vs APDN Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas APDN's P/E ratio is -0.10. In terms of profitability, BDSX's ROE is -7.88%, compared to APDN's ROE of -7.23%. Regarding short-term risk, BDSX is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
BDSX vs NVTA Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas NVTA's P/E ratio is -0.00. In terms of profitability, BDSX's ROE is -7.88%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, BDSX is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
BDSX vs LMDXW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, BDSX's ROE is -7.88%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, BDSX is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
BDSX vs LMDX Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas LMDX's P/E ratio is -0.01. In terms of profitability, BDSX's ROE is -7.88%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, BDSX is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check LMDX's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
BDSX vs BIAFW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, BIAFW has a market cap of 4.6M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while BIAFW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas BIAFW's P/E ratio is 0.49. In terms of profitability, BDSX's ROE is -7.88%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, BDSX is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check BIAFW's competition here
DermTech, Inc. (NASDAQ: DMTK)
BDSX vs DMTK Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas DMTK's P/E ratio is -0.04. In terms of profitability, BDSX's ROE is -7.88%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, BDSX is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
BDSX vs NOTV Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas NOTV's P/E ratio is -0.03. In terms of profitability, BDSX's ROE is -7.88%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, BDSX is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check NOTV's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
BDSX vs BIAF Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, BIAF has a market cap of 2.6M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while BIAF trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas BIAF's P/E ratio is -0.73. In terms of profitability, BDSX's ROE is -7.88%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, BDSX is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check BIAF's competition here
SeqLL Inc. (NASDAQ: SQL)
BDSX vs SQL Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas SQL's P/E ratio is -0.40. In terms of profitability, BDSX's ROE is -7.88%, compared to SQL's ROE of -30.46%. Regarding short-term risk, BDSX is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
BDSX vs AWH Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas AWH's P/E ratio is -0.09. In terms of profitability, BDSX's ROE is -7.88%, compared to AWH's ROE of +1.62%. Regarding short-term risk, BDSX is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
BDSX vs HTGM Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas HTGM's P/E ratio is -0.03. In terms of profitability, BDSX's ROE is -7.88%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, BDSX is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
BDSX vs BIOC Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas BIOC's P/E ratio is -0.01. In terms of profitability, BDSX's ROE is -7.88%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, BDSX is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
BDSX vs ISPC Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, ISPC has a market cap of 184.7K. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while ISPC trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas ISPC's P/E ratio is -0.04. In terms of profitability, BDSX's ROE is -7.88%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, BDSX is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
BDSX vs SQLLW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, BDSX's ROE is -7.88%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, BDSX is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
BDSX vs WGSWW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, BDSX's ROE is -7.88%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, BDSX is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check WGSWW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
BDSX vs MEUSW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas MEUSW's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, BDSX is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check MEUSW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
BDSX vs NDRAW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas NDRAW's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, BDSX is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
BDSX vs DHR-PA Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, BDSX's ROE is -7.88%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, BDSX is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check DHR-PA's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
BDSX vs PRXL Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas PRXL's P/E ratio is 42.97. In terms of profitability, BDSX's ROE is -7.88%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, BDSX is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check PRXL's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
BDSX vs OCDX Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas OCDX's P/E ratio is -42.28. In terms of profitability, BDSX's ROE is -7.88%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, BDSX is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for BDSX.Check OCDX's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
BDSX vs BNGOW Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas BNGOW's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, BDSX is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check BNGOW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
BDSX vs CHEKZ Comparison September 2026
Biodesix, Inc. (NASDAQ: BDSX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BDSX stands at 225.5M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, BDSX is priced at $28.17 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BDSX currently has a P/E ratio of -8.74, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, BDSX's ROE is -7.88%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, BDSX is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for BDSX.Check CHEKZ's competition here